No trading implication from this filing; standard equity grants for new hires. Monitor for larger personnel moves or clinical updates as potential catalysts.
IOVA drugs
IOVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $3.78entry
- T+1 · 7mo ago −2.12%α −1.46% · $3.70
- T+5 · 7mo ago −9.26%α −10.17% · $3.43
- T+20 · 6mo ago −10.32%α −14.52% · $3.39
- T+60 · 4mo ago +25.40%α +18.62% · $4.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Iovance Biotherapeutics granted inducement stock options covering 135,470 shares to twelve new non-executive employees, priced at $3.80 per share with three-year vesting. This is a routine hiring incentive and does not reflect a material strategic or financial change.
Key Facts
- Iovance granted stock options for 135,470 shares to twelve new non-executive employees.
- Options were granted under the 2021 Inducement Plan, compliant with Nasdaq Rule 5635(c)(4).
- Exercise price is $3.80, equal to the closing price on the grant date (April 16, 2026).
- Vesting: one-third on first anniversary, remainder over eight quarterly installments thereafter.
- No executive-level hires or material financial terms disclosed.
Financial Impact
Minimal near-term financial impact; dilution from 135,470 shares (~0.03% of 440M outstanding shares, based on $1.6B market cap).
Risk Factors
- Minor dilution over time as options vest.
- No performance conditions tied to vesting, though standard for inducement grants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276514 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers